03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Lamisil Tablets 125mg* : | |
Type | Medicine Withdrawn |
Originator | B |
Agent | Khalil Fattal & Fils |
Distributor | Khalil Fattal & Fils |
Laboratory | Novartis |
Responsible Party | Novartis Pharma AG |
Origin | Switzerland |
Manufacturer | Novartis Pharma AG |
Origin | Switzerland |
ATC | D01BA02 |
Lamisil Tablets 125mg* :
Lamisil Tablets 125mg* :
Lamisil Tablets 125mg* :
Lamisil Tablets 125mg* :
Lamisil Tablets 125mg* :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Lamisil Tablets 125mg* :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal bloating (Meteorism) | Very Common |
Abdominal pain | Very Common |
Acute generalised exanthematous pustulosis (AGEP) | Very rare |
Ageusia (Taste loss) | Uncommon |
Agranulocytosis | Very rare |
Alopecia | Very rare |
Anaemia | Not known |
Anaphylactic reactions | Not known |
Anaphylactoid reactions | Very rare |
Angioedema (Angioneurotic oedema) (Quincke oedema) | Very rare |
Anosmia (smell loss) | Not known |
Anxiety | Not known |
Arthralgia (Pain joint) (Joint ache) | Very Common |
Blood creatine phosphokinase increased | Not known |
Cephalea | Common |
Cholestasis | Not known |
Cutaneous lupus erythematosus | Very rare |
Decreased appetite | Very Common |
Depression | Not known |
Diarrhoea (Diarrhea) | Very Common |
Dyspepsia | Very Common |
Erythema multiforme | Very rare |
Fatigue | Very rare |
Flu-like syndrome | Not known |
Hearing loss | Not known |
Hepatic enzyme increased | Rare |
Hepatic failure (Hepatic insufficiency) (Liver failure) | Rare |
Hepatitis | Not known |
Hypoacusis | Not known |
Hypoesthesia | Very rare |
Hypogeusia | Uncommon |
Jaundice | Not known |
Lightheadedness | Very rare |
Lyell Syndrome (Toxic epidermal necrolysis) | Very rare |
Myalgia | Very Common |
Nausea | Very Common |
Neutropenia | Very rare |
Pancreatitis | Not known |
Pancytopenia | Very rare |
Paraesthesia (paresthesia) | Very rare |
Photosensitivity reaction | Uncommon |
Polymorphic light eruption | Uncommon |
Psoriasis aggravated (Psoriasis flare-up) | Very rare |
Pyrexia | Not known |
Rash psoriaform | Very rare |
Rhabdomyolysis | Not known |
Serum sickness-like reaction | Not known |
Skin Eruption | Very Common |
Stevens-Johnson syndrome | Very rare |
Systemic lupus erythematosus | Very rare |
Thrombocytopenia (Thrombopenia) | Very rare |
Tinnitus | Not known |
Urticaria | Very Common |
Vasculitides | Not known |
Weight decreased (Weight loss) | Not known |
Lamisil Tablets 125mg* :
NB : Products With Same Indication |
Different Units By MoH Code
Lamisil Tablets 125mg* MoH 3468 :
Form | Tablet, Scored |
Package Size | Box of 14 |
Strength | 125mg |
Storage Condition | <30°C protect from light |
Stratum | N/A |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 261326 |
Submission date | 01/01/1997 |
Registration Year | 1997 |
Archived Date | 2014 |
Withdrawn Date | 04/05/2021 |
Price Comparison
● Country: | Switzerland | |
● Package Size: | 14 | |
● Public Price: | 41.45 CHF | ( 4,286,759.00 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 2,9607 CHF | ( 206,840.00 LBP ) |
● Exfactory Price: | 21.83 CHF | |
● Pricing Date: | 04/04/2021 | |
● Type: | Medicine Authorised |
● Country: | Qatar | |
● Package Size: | 14 | |
● Public Price: | 79 QAR | ( 1,940,082.00 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 5,6429 QAR | ( 122,790.00 LBP ) |
● Pharmacy Price: | 64.8929866 QAR | ( 1593641.9649228 LBP ) |
● Pricing Date: | 28/01/2021 | |
● Type: | Medicine Authorised |
● Country: | UAE | |
● Package Size: | 14's Blister | |
● Public Price: | 78 AED | ( 1,884,558.00 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 5,5714 AED | ( 120,805.00 LBP ) |
● Pharmacy Price: | 62.88 AED | ( 1519243.68 LBP ) |
● Pricing Date: | 21/08/2019 | |
● Type: | Medicine Authorised |
● Country: | Abu Dhabi | |
● Package Size: | 14 | |
● Public Price: | 78 AED | ( 1,884,558.00 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 5,5714 AED | ( 120,805.00 LBP ) |
● Pharmacy Price: | 62.88 AED | ( 1519243.68 LBP ) |
● Pricing Date: | 27/01/2021 | |
● Type: | Medicine Authorised |
● Country: | Bahrain | |
● Package Size: | 14 | |
● Public Price: | 7.58 BHD | ( 1,802,023.72 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 0,5414 BHD | ( 0.00 LBP ) |
● Reference: | nhra | |
● Pricing Date: | 09/02/2021 | |
● Type: | Medicine Authorised |
● Country: | Cyprus | |
● Package Size: | 14 TABS | |
● Public Price: | 10.57 EUR | ( 1,023,979.32 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 0,755 EUR | ( 0.00 LBP ) |
● Reference: | Cyprus Minister of Health | |
● Pricing Date: | 24/03/2021 | |
● Type: | Medicine Authorised |
● Country: | Oman | |
● Package Size: | 14 | |
● Public Price: | 8.32 OMR | ( 1,919,706.88 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 0,5943 OMR | ( 0.00 LBP ) |
● Pricing Date: | 19/02/2021 | |
● Type: | Medicine Authorised |
● Country: | Jordan | |
● Package Size: | 14 | |
● Public Price: | 12.54 JOD | ( 1,570,271.34 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 0,8957 JOD | ( 0.00 LBP ) |
● Pharmacy Price: | 9.57 JOD | ( 1198364.97 LBP ) |
● Reference: | JFDA | |
● Pricing Date: | 02/01/2021 | |
● Type: | Medicine Authorised |
● Country: | Kuweit | |
● Package Size: | 14 | |
● Public Price: | 6.48 KWD | ( 1,902,404.88 LBP ) |
● Pack size unit used: | 14 | |
● Cost/Unit: | 0,4629 KWD | ( 0.00 LBP ) |
● Pharmacy Price: | 5.48 KWD | ( 1608823.88 LBP ) |
● Pricing Date: | 07/02/2021 | |
● Type: | Medicine Authorised |
Note
You have to register to view this info
Drop File